Launch excellence – adapting to data disruption
In Danny Buckland’s article on launch excellence this month, he looks at the effect the global pandemic has had on the pharmaceutical industry over the past few years and how industry is meeting today’s challenges with innovation and long-term vision.
As Danny says: “The pivot to digital and the adoption of a new suite of processes – and ways of accomplishing them – has caused degrees of corporate darkness but it has also revealed diamonds of understanding and engagement that are illuminating a new era of commercial launch excellence.
“Sobering statistics back up [the pandemic’s impact on drug launches], with analysts McKinsey recording that 40% of drug launches from 2009 to 2017 failed to meet their two-year sales goals and Trinity Life Sciences revealing that 62% of drug launches between September 2019 and December 2021 ‘underperformed expectations’.”
Read more on page 30.
In our article by Gen Li, president and founder of Phesi, he talks about preparing for the clinical trials of the future and how, with access to more data than ever before, now is the time for the industry to modernise, become data-led and boost patient experience. Read more on page 16.
Our article from Matt Angel, CEO of Eterna Therapeutics looks at the impact of cell therapies on cancer treatments, how research using cell therapies to treat cancer has improved in the last decade and how these therapies benefit patients. Read more on page 22.
Looking ahead, our November issue will focus on the value of real-world studies. If you would like to make your voice heard on this topic, please get in touch at sales@pmlive.com
I hope you enjoy this issue!
